Activation of phosphatidylinositol-3′-kinase/AKT signaling is essential in hepatoblastoma survival

Clinical Cancer Research

Volumn 15, Issue 14, 2009, Pages 4538-4545

  Hartmann, Wolfgang ^a   Küchler, Jan ^a   Koch, Arend ^a,b   Friedrichs, Nicolaus ^a   Waha, Anke ^a   Endl, Elmar ^a   Czerwitzki, Jacqueline ^a   Metzger, Dagmar ^a   Steiner, Susanne ^a   Wurst, Peter ^a   Leuschner, Ivo ^c   Von Schweinitz, Dietrich ^d   Buettner, Reinhard ^a   Pietsch, Torsten ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c UNIVERSITY OF KIEL   (Germany)

^d UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; GLYCOGEN SYNTHASE KINASE 3BETA; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GENE EXPRESSION; GENE MUTATION; HEPATOBLASTOMA; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL;

ADOLESCENT; ADULT; APOPTOSIS; CELL LINE, TUMOR; CELL SURVIVAL; CHILD; CHILD, PRESCHOOL; CHROMONES; CISPLATIN; DRUG SYNERGISM; FLOW CYTOMETRY; GLYCOGEN SYNTHASE KINASE 3; HEPATOBLASTOMA; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; MORPHOLINES; MUTATION; NUCLEAR PROTEINS; PHOSPHORYLATION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROTEIN KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; YOUNG ADULT;

EID: 68049113683     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-2878     Document Type: Article

References (33)

1. Stiller CA, Pritchard J, Steliarova-Foucher E. Liver cancer in European children: incidence and survival, 1978-1997. Report from the Automated Childhood Cancer Information System project. Eur J Cancer 2006;42:2115-2123
2. Albrecht S, von Schweinitz D, Waha A, Kraus JA, von Deimling A, Pietsch T. Loss of maternal alleles on chromosome arm 11p in hepatoblastoma. Cancer Res 1994;54:5041-5044 (Pubitemid 24313472)
3. Li X, Adam G, Cui H, Sandstedt B, Ohlsson R, Ekstrom TJ. Expression, promoter usage and parental imprinting status of insulin-like growth factor II (IGF2) in human hepatoblastoma: uncoupling of IGF2 and H19 imprinting. Oncogene 1995;11:221-229
4. Hartmann W, Waha A, Koch A, et al. p57(KIP2) is not mutated in hepatoblastoma but shows increased transcriptional activity in a comparative analysis of the three imprinted genes p57(KIP2), IGF2, and H19. Am J Pathol 2000;157:1393-1403 (Pubitemid 30757959)
5. Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 1995;378:785-789 (Pubitemid 26004411)
6. Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2002;2:489-501. (Pubitemid 37328931)
7. Osaki M, Oshimura M, Ito H. PI3K-Akt pathway: its functions and alterations in human cancer. Apoptosis 2004;9:667-676 (Pubitemid 40941196)
8. Diehl JA, Cheng M, Roussel MF, Sherr CJ. Glycogen synthase kinase-3β regulates cyclin D1 proteolysis and subcellular localization. Genes Dev 1998;12:3499-3511 (Pubitemid 28553242)
9. Bjornsti MA, Houghton PJ. The TOR pathway: a target for cancer therapy. Nat Rev Cancer 2004;4:335-348 (Pubitemid 38579480)
10. G-Amlak M, Uddin S, Mahmud D, et al. Regulation of myeloma cell growth through Akt/Gsk3/forkhead signaling pathway. Biochem Biophys Res Commun 2002;297:760-764 (Pubitemid 35230315)
11. Liang J, Slingerland JM. Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression. Cell Cycle 2003;2:339-345
12. Sherr CJ. Cancer cell cycles. Science 1996;274:1672-1677
13. Samuels Y, Wang Z, Bardelli A, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004;304:554. (Pubitemid 38541907)
14. Broderick DK, Di C, Parrett TJ, et al. Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas. Cancer Res 2004;64:5048-5050
15. Doi L. Establishment of a cell line and its clonal sublines from a patient with hepatoblastoma. Gann 1976;67:1-10.
16. Pietsch T, Fonatsch C, Albrecht S, Maschek H, Wolf HK, von Schweinitz D. Characterization of the continuous cell line HepT1 derived from a human hepatoblastoma. Lab Invest 1996;74:809-818 (Pubitemid 26117140)
17. Hartmann W, Koch A, Brune H, et al. Insulin-like growth factor II is involved in the proliferation control of medulloblastoma and its cerebellar precursor cells. Am J Pathol 2005;166:1153-1162 (Pubitemid 40524439)
18. Baohua Y, Xiaoyan Z, Tiecheng Z, Tao Q, Daren S. Mutations of the PIK3CA gene in diffuse large B cell lymphoma. Diagn Mol Pathol 2008;17:159-165
19. Kang S, Seo SS, Chang HJ, Yoo CW, Park SY, Dong SM. Mutual exclusiveness between PIK3CA and KRAS mutations in endometrial carcinoma. Int J Gynecol Cancer 2008;18:1339-1343
20. Kang S, Bader AG, Vogt PK. Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc Natl Acad Sci U S A 2005;102:802-807 (Pubitemid 40282746)
21. Zhang J, Hu S, Schofield DE, Sorensen PH, Triche TJ. Selective usage of D-Type cyclins by Ewing's tumors and rhabdomyosarcomas. Cancer Res 2004;64:6026-6034 (Pubitemid 39129400)
22. Hartmann W, Digon-Sontgerath B, Koch A, et al. Phosphatidylinositol 3′-kinase/AKT signaling is activated in medulloblastoma cell proliferation and is associated with reduced expression of PTEN. Clin Cancer Res 2006;12:3019-3027 (Pubitemid 43837346)
23. Toretsky JA, Helman LJ. Involvement of IGF-II in human cancer. J Endocrinol 1996;149:367-372
24. Tomizawa M, Saisho H. Signaling pathway of insulin-like growth factor-II as a target of molecular therapy for hepatoblastoma. World J Gastroenterol 2006;12:6531-6535 (Pubitemid 44742590)
25. Bader AG, Kang S, Zhao L, Vogt PK. Oncogenic PI3K deregulates transcription and translation. Nat Rev Cancer 2005;5:921-929 (Pubitemid 41766781)
26. 1 to S transition is mediated by effects on cyclin D1 mRNA and protein stability. J Biol Chem 1998;273:14424-14429
27. Rossig L, Badorff C, Holzmann Y, Zeiher AM, Dimmeler S. Glycogen synthase kinase-3 couples AKT-dependent signaling to the regulation of p21Cip1 degradation. J Biol Chem 2002;277:9684-9689 (Pubitemid 34968067)
28. Koch A, Denkhaus D, Albrecht S, Leuschner I, von Schweinitz D, Pietsch T. Childhood hepatoblastomas frequently carry a mutated degradation targeting box of the beta-catenin gene. Cancer Res 1999;59:269-273 (Pubitemid 29048850)
29. Koch A, Waha A, Hartmann W, et al. Elevated expression of Wnt antagonists is a common event in hepatoblastomas. Clin Cancer Res 2005;11:4295-4304 (Pubitemid 40825616)
30. Behrens J. Control of β-catenin signaling in tumor development. Ann N Y Acad Sci 2000;910:21-33; discussion 33-125 (Pubitemid 30462055)
31. Datta SR, Dudek H, Tao X, et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997;91:231-241 (Pubitemid 27456390)
32. Maurer U, Charvet C, Wagman AS, Dejardin E, Green DR. Glycogen synthase kinase-3 regulates mitochondrial outer membrane permeabilization and apoptosis by destabilization of MCL-1. Mol Cell 2006;21:749-760 (Pubitemid 43376126)
33. Opel D, Westhoff MA, Bender A, Braun V, Debatin KM, Fulda S. Phosphatidylinositol 3-kinase inhibition broadly sensitizes glioblastoma cells to death receptor- and drug-induced apoptosis. Cancer Res 2008;68:6271-6280